ASSURE: Dose Reduction of Sunitinib or Sorafenib Not Associated With Improved Outcomes in Resected RCC

May 29-June 2, 2015; Chicago, Illinois
Results of a dose amendment to the phase III ASSURE trial; impact on safety and clinical outcome discussed.
Format: Microsoft PowerPoint (.ppt)
File Size: 448 KB
Released: June 4, 2015


Educational grant provided by:
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Novartis Pharmaceuticals Corporation

Related Content

Download slides from Clinical Care Options examining the optimal use of VEGFR-targeted TKIs in treating patients with solid organ tumors.

Tanios Bekaii-Saab Tanios Bekaii-Saab, MD, FACP Richard Finn, MD Elizabeth R. Plimack, MD, MS Released: November 15, 2019

In this activity from Clinical Care Options, experts discuss the latest data on treating solid organ tumors with VEGFR inhibitors.

Tanios Bekaii-Saab Tanios Bekaii-Saab, MD, FACP Richard Finn, MD Elizabeth R. Plimack, MD, MS Released: November 15, 2019

Download this free slideset by Todd M. Bauer, MD, for a brief overview of the optimal treatment options for patients with NTRK, ROS1, FGFR, or RET altered tumors.

Todd M. Bauer, MD Released: June 3, 2019

Downloadable PDF resource summarizing FDA-approved immunotherapy indications and complementary diagnostics for PD-L1 in multiple malignancies.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Axel Grothey Headshot Axel Grothey, MD Michael J. Pishvaian, MD, PhD David R. Spigel, MD
Released: May 31, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?